Nama's AI scorecard currently rates Azenta Sell (4.1 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is AZTA's P/E ratio?

Azenta trades at a trailing price-to-earnings ratio of 93.2.

When does AZTA report earnings?

Azenta's next scheduled report is on Nov 10, 2026. Analysts expect EPS of $0.11.

What is the AZTA price target?

The median analyst price target from 5 analysts is $37.00, with a range of $33.00 – $44.00.

Is AZTA Shariah compliant?

Nama's AAOIFI-style screen reads Azenta as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Nama Insights

Azenta (AZTA)

Healthcare · Medical Instruments Supplies · NASDAQ

Azenta (AZTA) is a Healthcare company in the Medical Instruments Supplies industry. It has a market capitalization of $1.72B, a trailing price-to-earnings ratio of 93.2 and a free-cash-flow yield of 2.3%. Over the most recent reported fiscal year, revenue grew 3.5% and free cash flow per share grew 229.6%. Nama's AI scorecard rates it Sell, 4.1 out of 10. On 12-month momentum it ranks in the middle band of its market.

AI scorecard

Sell · 4.1/10

Negative, at the mild end of Sell. As of Nov 7, 2026.

Momentum

Middle · +21.5% over 12 months ex. last

Middle fifth of its market on the past year's move.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-68.6%

How far the last close sits under the highest price of the past five years.

Market cap	$1.72B
Trailing P/E	93.2
Price / book	1.1
Price / sales	2.8
FCF yield	2.3%
Dividend yield	—
Gross margin	43.4%
Operating margin	-3.8%
Net margin	-20.0%
Revenue growth (YoY)	+3.5%
Revenue growth (3-yr annual)	+2.2%
EPS growth (YoY)	+29.3%
FCF/share growth (YoY)	+229.6%
Beta	1.5
Exchange	NASDAQ
Sector	Healthcare
Industry	Medical Instruments Supplies

AZTA earnings

Next report: Nov 10, 2026 (Q4 2026, EPS estimate $0.11). Beat the EPS estimate in 2 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Aug 4, 2026	$0.16	$0.10	+60.0%	$161.18M
Q2 2026	May 5, 2026	-$0.04	$0.14	-128.6%	$144.79M
Q1 2026	Feb 4, 2026	$0.09	$0.13	-30.8%	$148.64M
Q4 2025	Nov 21, 2025	$0.21	$0.20	+5.0%	$158.95M

AZTA analyst price target

Median target $37.00 from 5 analysts, ranging $33.00 – $44.00.

Medical Instruments Supplies peers

Ticker	Company	Market cap	P/E
ISRG	Intuitive Surgical	$159.96B	41.8
BDX	Becton, Dickinson	$57.71B	16.1
MDLN	Medline	$52.17B	25.1
ALC	Alcon	$36.23B	23.0
RMD	ResMed	$33.10B	20.4
WST	West Pharmaceutical Services	$27.85B	43.5
SOLV	Solventum	$15.38B	12.8
BAX	Baxter International	$13.34B	13.3

Explore live AZTA data on Nama Insights →

Recent Congressional trades

Azenta trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Gilbert Cisneros	House	Buy	$1,001 - $15,000	Feb 13, 2026
Josh Gottheimer	House	Sell	$1,001 - $15,000	Apr 10, 2025
Josh Gottheimer	House	Sell	$1,001 - $15,000	Oct 15, 2023
Josh Gottheimer	House	Buy	$1,001 - $15,000	Aug 21, 2023

AZTA FAQ

Is AZTA a buy?: Nama's AI scorecard currently rates Azenta Sell (4.1 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is AZTA's P/E ratio?: Azenta trades at a trailing price-to-earnings ratio of 93.2.
When does AZTA report earnings?: Azenta's next scheduled report is on Nov 10, 2026. Analysts expect EPS of $0.11.
What is the AZTA price target?: The median analyst price target from 5 analysts is $37.00, with a range of $33.00 – $44.00.
Is AZTA Shariah compliant?: Nama's AAOIFI-style screen reads Azenta as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.